Compare Aurobindo Pharma with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA STRIDES PHARMA SCIENCE AUROBINDO PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 18.4 47.0 39.2% View Chart
P/BV x 4.0 2.2 181.8% View Chart
Dividend Yield % 0.3 0.2 119.2%  

Financials

 AUROBINDO PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
AUROBINDO PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs8301,147 72.4%   
Low Rs527642 82.1%   
Sales per share (Unadj.) Rs333.9317.2 105.2%  
Earnings per share (Unadj.) Rs40.47.8 514.4%  
Cash flow per share (Unadj.) Rs51.825.1 206.6%  
Dividends per share (Unadj.) Rs2.502.00 125.0%  
Dividend yield (eoy) %0.40.2 164.8%  
Book value per share (Unadj.) Rs237.1274.3 86.4%  
Shares outstanding (eoy) m585.9189.50 654.6%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.02.8 72.1%   
Avg P/E ratio x16.8114.0 14.7%  
P/CF ratio (eoy) x13.135.7 36.7%  
Price / Book Value ratio x2.93.3 87.8%  
Dividend payout %6.225.5 24.3%   
Avg Mkt Cap Rs m397,56980,058 496.6%   
No. of employees `00017.92.5 712.2%   
Total wages/salary Rs m25,8494,341 595.5%   
Avg. sales/employee Rs Th10,956.911,325.8 96.7%   
Avg. wages/employee Rs Th1,447.71,731.4 83.6%   
Avg. net profit/employee Rs Th1,324.3280.1 472.9%   
INCOME DATA
Net Sales Rs m195,63628,394 689.0%  
Other income Rs m1,553941 165.1%   
Total revenues Rs m197,18929,334 672.2%   
Gross profit Rs m39,5193,965 996.6%  
Depreciation Rs m6,6801,540 433.6%   
Interest Rs m2,6261,962 133.8%   
Profit before tax Rs m31,7671,403 2,263.9%   
Minority Interest Rs m270-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m-881-436 202.1%   
Tax Rs m7,26997 7,470.2%   
Profit after tax Rs m23,645702 3,367.8%  
Gross profit margin %20.214.0 144.6%  
Effective tax rate %22.96.9 330.0%   
Net profit margin %12.12.5 488.8%  
BALANCE SHEET DATA
Current assets Rs m153,64524,836 618.6%   
Current liabilities Rs m120,42918,993 634.1%   
Net working cap to sales %17.020.6 82.5%  
Current ratio x1.31.3 97.6%  
Inventory Days Days13571 190.5%  
Debtors Days Days64113 56.2%  
Net fixed assets Rs m103,90934,289 303.0%   
Share capital Rs m586895 65.5%   
"Free" reserves Rs m138,32223,651 584.9%   
Net worth Rs m138,90824,546 565.9%   
Long term debt Rs m1,80015,513 11.6%   
Total assets Rs m264,54465,437 404.3%  
Interest coverage x13.11.7 763.7%   
Debt to equity ratio x00.6 2.0%  
Sales to assets ratio x0.70.4 170.4%   
Return on assets %9.94.1 243.9%  
Return on equity %17.02.9 595.1%  
Return on capital %23.86.9 345.7%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31615,697 620.0%   
Fx outflow Rs m40,589735 5,519.3%   
Net fx Rs m56,72714,962 379.1%   
CASH FLOW
From Operations Rs m16,2201,871 867.1%  
From Investments Rs m-28,7685,826 -493.8%  
From Financial Activity Rs m19,191-10,157 -188.9%  
Net Cashflow Rs m6,656-2,615 -254.6%  

Share Holding

Indian Promoters % 54.1 27.7 195.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 37.8 21.0%  
FIIs % 27.7 8.6 322.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 25.9 39.4%  
Shareholders   69,601 56,241 123.8%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ABBOTT INDIA  JUBILANT PHARMOVA   AJANTA PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher, Dow Futures Down by 28 Points(12:30 pm)

Share markets in India are presently trading marginally higher. The BSE Sensex is trading up by 74 points, up 0.2% at 48,877 levels.

Related Views on News

DISHMAN CARBOGEN AMCIS Share Price Up by 5%; BSE HEALTHCARE Index Up 1.0% (Market Updates)

Apr 16, 2021 | Updated on Apr 16, 2021

DISHMAN CARBOGEN AMCIS share price is trading up by 5% and its current market price is Rs 123. The BSE HEALTHCARE is up by 1.0%. The top gainers in the BSE HEALTHCARE Index are DISHMAN CARBOGEN AMCIS (up 5.5%) and STRIDES PHARMA SCIENCE (up 5.7%). The top losers are SANOFI INDIA and TORRENT PHARMA (down 0.1%).

STRIDES PHARMA SCIENCE Share Price Up by 5%; BSE HEALTHCARE Index Up 0.8% (Market Updates)

Apr 16, 2021 | Updated on Apr 16, 2021

STRIDES PHARMA SCIENCE share price is trading up by 5% and its current market price is Rs 898. The BSE HEALTHCARE is up by 0.8%. The top gainers in the BSE HEALTHCARE Index is STRIDES PHARMA SCIENCE (up 5.1%). The top losers are TORRENT PHARMA (down 0.1%) and J.B.CHEMICALS (down 0.2%).

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday(Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Apr 16, 2021 01:49 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS